Established in 1997, NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC has been striving to become a world-class innovative biotechnology company in pharmaceutical industry. We are proud to be the leading company in Asia-Pacific region that successfully researched and developed Active Pharmaceutical Ingredients (APIs) and specific therapeutic products on the foundation of advanced recombinant DNA/protein technology.
After more than 20 years of tireless research, NANOGEN has successfully offered a variety of gene-to-therapy biopharmaceuticals for the treatment of cancer, hepatitis B, hepatitis C, anemia due to chronic renal failure,… Besides, NANOGEN has been inventing and conducting clinical trials on monoclonal antibodies for oncology immunotherapy as well as Covid-19 vaccine and treatment.
Our facilities including 4 Factories and 1 R&D Center are located in 3 provinces of Vietnam with the total area of 73 000 square meters. Our manufacturing systems and processes are operated under strict quality standards of WHO-GMP and TGA-GMP. With the capacity of more than 50 million products each year, NANOGEN has delivered products to 15 countries in Asia, Europe, Africa and America.
NANOGEN’s main goal is to improve the production process and enhance research activities to manufacture high quality, safe, effective and affordable products for more patients in the world.